Volume : 10, Issue : 06, June – 2023
Title:
20.A REVIEW ON PHARMACOVIGILANCE PROGRAMME OF INDIA
Authors :
Soorya S*, Jino Syam J S*, Ganga Devi S*, Dr Jayachandran Nair CV, Dr Prasobh GR
Abstract :
In India, a proper adverse drug reaction monitoring system was started in 1986 with 12 regional centres. In 1997, India became the member of World health organization Programme for International Drug watching managed by the Upsala Monitoring Centre, Sweden. At origination, 6 regional centres were created in Mumbai, New Delhi, Kolkata, Lucknow, Pondicherry, and Chandigarh for ADR watching within the country. Promoting safe use of drugs may be a priority of Indian Pharmacopoeia Commission that functions as the National Coordination Centre for Pharmacovigilance Programme of India. There are 701 Adverse Drug Reactions Monitoring Centres presently report adverse events to National coordinative centre in India.
Keywords: Adverse drug reaction, AMC, Pharmacovigilance
Cite This Article:
Please cite this article in press Soorya S et al, A Review On Pharmacovigilance Programme Of India., Indo Am. J. P. Sci, 2023; 10 (06).
Number of Downloads : 10
References:
1. Nimesh S and Ashwlayan VD. “Pharmacovigilance: An Overview”. International Journal of Pharmacovigilance 3.1 (2018):1-6.
2. Central TB Division. “Directorate general of health services,ministry of health and family welfare.TB India 2006. RNTCP status report. New Delhi, India: MFHW (2006).
3. US National Library of Medicine. Rx Norm APIs. Accessed from(2017). Srivastava SK. “A complete textbook of medical pharmacology”. 1st edition, Chapter 56 (2017) 888.
4. The Bio-Medical Waste Management (Amendment) Rules(2018).7. Mohamed B Elnagar I. “Prevalence and Extent of Adverse Drug Reactions in Sudanese Patients in Highly Active Anti retro viral Therapy Regimens”. International Journal of Pharmacovigilance 2.2 (2017): 1-12.
5. Zhu Z., et al. “Selective upper airway stimulation in older patients”. Respiratory Medicine 140 (2018): 77-81.
6. Najafi S. “Importance of Pharmacovigilance and the Role ofHealthcare Professionals”. Journal of Pharmacovigilance 6.1(2018): 1-2.
7. WHO Drug Information. “Pharmacovigilance Programme of India. Safety of medicines”. The journey travelled and the way forward 32.1 (2018): 11-17.
8. Routledge P. “150 years of pharmacovigilance”. The Lancet 351.9110 (2018): 1200-1201.
9. PvPI Reaches out to rural masses, 2017. Newsletter Pharmacovigilance Programme of India. Pharmacovigilance and Risk Management Strategies Forum. 5th Annual Flemming Conference, Philadelphia, PA (2017).
10. Parthasarathi G., et al. “Pharmacovigilance Research in India: A Five-Year Literature Review”. Proceedings of the Indian National Science Academy 8 (2018): 225-232.
11. Khan MA., et al. “Assessment of prescribing trend of drugs at outpatient’s chest ward of government tertiary care hospital situated in karachi”. Journal of Bioequivalence and Bioavailability 10.1 (2018): 1-4.
12. Birungi FM., et al. “Assessment of the isoniazid preventive therapy uptake and associated characteristics: a crosss ectional study”. Tuberculosis Research and Treatment (2018): 1-9.
13. Kalaiselvan V., et al. “Pharmacovigilance Programme of India: Recent developments and future perspectives”. Indian Journal of Pharmacology 48.6 (2016): 624-628.
14. Bester K., et al. “Anaesthesia for paediatric patients: Minimising the risk”. South African Medical Journal 108.6 (2018): 457-459.